BIOE Bio Essence Corp

BIOE financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1723059 Exchange: OTC SIC: 2834 (Pharmaceutical Preparations) Latest filing: 10-Q filed Nov 13, 2026 Data checked: Nov 16, 2026
Showing 3 of 6 annual and 0 of 27 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
<br>Emerging growth company
Entity Type
Operating
Public Float
$26.84M (Dec 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
CA
Fiscal Year End
December (1231)
Phone
888-816-1494
EIN
943349551
Headquarters
IRVINE, CA
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.

▼ Key Metrics (TTM)

As of Sep 30, 2026
Financials
Revenue
$3.03M
Net Income
$1.35M
Total Assets
$4.00M
Total Equity
$2.29M
Total Debt
-
Free Cash Flow
-
Ratios
Gross Margin
68.4%
Operating Margin
45.1%
Net Margin
44.7%
Return on Equity
59.1%
Return on Assets
33.8%
Current Ratio
0.17x

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

Fiscal 2025 results for Bio Essence Corp combined $1.90M of revenue with net income of $896.20K and an operating cash inflow of $1.57M. The $1.90M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. Compared with $323.94K in fiscal 2024, revenue recorded a 485.8% year-over-year increase. A diluted share base of 38.01M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. The diluted share count was 0.0% higher than fiscal 2024, when diluted shares averaged 38.01M, adding context to the EPS comparison. Total assets stood at $422.47K, showing the scale of resources supporting revenue, earnings, liquidity, and financing. Asset turnover was 4.49x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

After reported cost of revenue, the company retained $1.43M as gross profit before recognizing operating expenses and other items. Gross margin was 75.3%, so that share of each revenue unit remained after the cost of revenue reported for the period. The reported operating result was $900.01K, capturing profitability after direct costs and the operating expenses reflected in the statements. Operating margin measured 47.4%, showing the portion of revenue preserved after the full set of operating costs. After all reported below-operating-line items, the company recorded net income of $896.20K for the fiscal year. Measured against reported revenue, net income produced a 47.2% margin after operating costs and the remaining recognized items. EBITDA was $900.25K, adding a pre-interest, tax, depreciation, and amortization view of the company’s earnings capacity. The earnings statement records $897.00K of pretax income, the profit base against which the reported tax provision can be assessed. Measured against revenue, pretax income equaled 47.3%, adding a pre-tax profitability layer between revenue and net income. Income tax expense totaled $800.00, providing the reported tax component that separates pretax and after-tax earnings. Relative to pretax income, the tax provision measured 0.1%, quantifying the portion of pre-tax earnings paid in income tax. Net income represented 212.1% of period-end assets, placing the company’s bottom-line result against the total resource base employed. Net income of $896.20K replaced the $1.31M loss reported in fiscal 2024.

Liquidity and Capital Structure

The company held $422.47K of assets against $2.50M of liabilities and -$2.07M of equity, revealing how the asset base was financed. With total equity at -$2.07M, the company carried a negative book-capital position, increasing its reliance on liabilities and future earnings. Current assets were $422.38K against $2.44M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. Current assets covered only 0.17x of current liabilities, so current liabilities exceeded current assets at period end. The company carried $57.48K of total debt at period end, which frames its leverage and debt-service burden. Debt represented 13.6% of total assets, placing borrowing in the context of the company’s full resource base. The equity-to-assets relationship was -490.7%, placing book capital against the total resource base. Relative to total assets, liabilities measured 590.7%, complementing the separate equity-based view of the company’s capital structure. The asset base changed 50.3% from $281.02K in fiscal 2024, leaving current total assets higher year over year.

Cash Flow and Earnings Quality

Cash flow from operations was $1.57M, a reported cash inflow that can be compared directly with net income and capital spending. The operating-cash-flow-to-net-income relationship was 1.75x, comparing cash generated by operations with the bottom-line earnings result. Operating cash flow of $1.57M finished above fiscal 2024 operating cash flow of $623.87K, showing the year-over-year direction of cash generation.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for Bio Essence Corp
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $1.90M $323.94K $551.51K
Cost of Revenue $469.15K $106.86K $274.06K
Gross Profit $1.43M $217.08K $277.45K
OPERATING EXPENSES
SG&A Expense $497.81K $676.52K $345.59K
Operating Income $900.01K $-459.44K $-345.59K
NON-OPERATING INCOME / EXPENSE
Interest Expense - - $17.34K
Other Income/Expense $-3.01K $-1.11M $-11.10K
Pretax Income $897.00K $-1.56M $-403.00K
Income Tax $800 $800 $1.60K
Net Income $896.20K $-1.31M $-971.88K
PER SHARE & SUPPLEMENTAL
Diluted EPS - $-0.03 $-0.03
Diluted Shares 38.01M 38.01M 35.95M
EBITDA $900.25K $-458.53K $-340.80K
Depreciation & Amortization $235 $911 $4.79K
Balance Sheet
ASSETS
Cash & Equivalents - $1.37K $114
Accounts Receivable $23.45K $5.12K $35.09K
Inventory - - $143.26K
Other Current Assets $3.75K $202.24K $5.63K
Current Assets $422.38K $280.69K $300.00K
PP&E (Net) - - $3.69K
Intangible Assets $97 $332 $567
Other Noncurrent Assets - $332 $1.48M
Noncurrent Assets $97 $332 $2.46M
Total Assets $422.47K $281.02K $2.76M
LIABILITIES
Accounts Payable $47.88K $17.74K $12.45K
Current Liabilities $2.44M $2.80M $2.45M
Long-term Debt $57.48K $56.48K -
Other Noncurrent Liabilities (derived) $-1.33K $447.41K $991.53K
Noncurrent Liabilities $56.16K $447.41K $1.14M
Total Liabilities $2.50M $3.25M $4.42M
EQUITY
Common Stock $3.80K $3.80K $3.80K
Additional Paid-in Capital $7.48M $7.48M $7.48M
Retained Earnings $-9.55M $-10.45M $-9.14M
Total Equity $-2.07M $-2.97M $-1.66M
Total Liabilities & Equity $422.47K $281.02K $2.76M
SUPPLEMENTAL
Shares Outstanding 38.01M 38.01M 38.01M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $1.57M $623.87K $-1.03M
Capital Expenditures - - $3.61K
Cash from Investing - $-114 $-91.48K
Cash from Financing $-1.57M $-622.49K $1.11M
Free Cash Flow - - $-1.03M
Beginning Cash (CFS) $1.37K $114 $6.26K
Net Change in Cash - $1.26K $-6.15K
Effect of FX on Cash - - -
Calculated Ending Cash - $1.37K $114
Cash per BS - $1.37K $114
Cash scope difference (CFS − BS) - - -
Cash per CFS - $1.37K $114

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is Bio Essence Corp's annual revenue?

Bio Essence Corp reported $3.03M in revenue for trailing twelve months (ending September 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is Bio Essence Corp profitable?

Yes. Bio Essence Corp reported $1.35M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.